This year witnessed simultaneous major advances across multiple research domains: the PREEMPT trials establishing OnabotulinumtoxinA for chronic migraine treatment (24), studies elucidating CGRP’s pathophysiological role (25) and photophobia mechanisms (26), genome-wide association studies identifying novel susceptibility loci (27), and the discovery of TRESK potassium channel mutations in familial migraine with aura (28). The gene discussed is CALCA; the disease is Photophobia.